Alirocumab (anti-PCSK9), CAS 1245916-14-6

Product Description: Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia[1][2].

Applications: Neuroscience-Neuromodulation

Formula: N/A

References: [1]Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705./[2]Tavori H, et al. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44.

CAS Number: 1245916-14-6

Molecular Weight: N/A

Compound Purity: 98.24

Research Area: Cardiovascular Disease; Cancer

Solubility: H2O

Target: PCSK9

• Artikelnummer: MEXHY-P9928A-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9928A-1
• Verpackungseinheit: 1mg
• Mengeneinheit: STK
• Konjugat: Unconjugated